The molecular pathogenesis of Ewing's sarcoma

Cancer Biology and Therapy

Volumn 9, Issue 9, 2010, Pages 653-665

  Mackintosh, Carlos ^a   Madoz Gúrpide, Juan ^b   Ordóñez, Jose Luis ^a   Osuna, Daniel ^a   Herrero Martín, David ^c  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^c UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Ewing's sarcoma; EWS ETS; Molecular targets; Mouse models; Novel therapies; Pediatric; Signaling pathways

Indexed keywords

CHIMERIC PROTEIN; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M4; HYBRID PROTEIN; PHOSPHOTRANSFERASE INHIBITOR; TELOMERASE; TRANSCRIPTION FACTOR ER81; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; WNT PROTEIN; AURORA A KINASE; BETA CATENIN; CYCLIN D1; DISHEVELLED PROTEIN; FRIZZLED PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN P21; RAC PROTEIN; RAS PROTEIN; RHO FACTOR; RHO KINASE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; STEM CELL FACTOR; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; WNT5A PROTEIN;

ALLELE; AMINO TERMINAL SEQUENCE; CANCER IMMUNOTHERAPY; CELL THERAPY; CHROMOSOME TRANSLOCATION; DNA BINDING; DOWN REGULATION; EWING SARCOMA; GENE EXPRESSION; GENE FUNCTION; GENE FUSION; GENE MUTATION; GENE TARGETING; HUMAN; IMMUNE SYSTEM; INTRACELLULAR SIGNALING; KNOCKOUT GENE; MESENCHYMAL STEM CELL; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; RNA BINDING; SIGNAL TRANSDUCTION; UPREGULATION; XENOGRAFT; PATHOPHYSIOLOGY; PHYSIOLOGY; MOLECULAR PATHOLOGY;

HUMANS; SARCOMA, EWING'S; SIGNAL TRANSDUCTION;

EID: 77953713665     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: None     Document Type: Review

References (204)

1. Kovar H, Aryee D, Zoubek A. The Ewing family of tumors and the search for the Achilles' heel. Curr Opin Oncol 1999; 11:275-84. (Pubitemid 29312747)
2. Bennicelli JL, Barr FG. Chromosomal translocations and sarcomas. Curr Opin Oncol 2002; 14:412-9.
3. Lessnick SL, Braun BS, Denny CT, May WA. Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene. Oncogene 1995; 10:423-31.
4. Ohno T, Ouchida M, Lee L, Gatalica Z, Rao VN, Reddy ES. The EWS gene, involved in Ewing family of tumors, malignant melanoma of soft parts and desmoplastic small round cell tumors, codes for an RNA binding protein with novel regulatory domains. Oncogene 1994; 9:3087-97. (Pubitemid 24296791)
5. Aman P, Panagopoulos I, Lassen C, Fioretos T, Mencinger M, Toresson H, et al. Expression patterns of the human sarcoma-associated genes FUS and EWS and the genomic structure of FUS. Genomics 1996; 37:1-8.
6. Bertolotti A, Lutz Y, Heard DJ, Chambon P, Tora L. hTAF(II)68, a novel RNA/ssDNA-binding protein with homology to the pro-oncoproteins TLS/FUS and EWS is associated with both TFIID and RNA polymerase II. EMBO J 1996; 15:5022-31.
7. Bailly RA, Bosselut R, Zucman J, Cormier F, Delattre O, Roussel M, et al. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol 1994; 14:3230-41.
8. Wasylyk B, Hahn SL, Giovane A. The Ets family of transcription factors. Eur J Biochem 1993; 211:7-18.
9. Sementchenko VI, Watson DK. Ets target genes: past, present and future. Oncogene 2000; 19:6533-48.
10. Sharrocks AD. The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2001; 2:827-37.
11. May WA, Gishizky ML, Lessnick SL, Lunsford LB, Lewis BC, Delattre O, et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci USA 1993; 90:5752-6.
12. Kim S, Denny CT, Wisdom R. Cooperative DNA binding with AP-1 proteins is required for transformation by EWS-Ets fusion proteins. Mol Cell Biol 2006; 26:2467-78.
13. Toretsky JA, Erkizan V, Levenson A, Abaan OD, Parvin JD, Cripe TP, et al. Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. Cancer Res 2006; 66:5574-81.
14. Petermann R, Mossier BM, Aryee DN, Khazak V, Golemis EA, Kovar H. Oncogenic EWS-Fli1 interacts with hsRPB7, a subunit of human RNA polymerase II. Oncogene 1998; 17:603-10.
15. Deneen B, Hamidi H, Denny CT. Functional analysis of the EWS/ETS target gene uridine phosphorylase. Cancer Res 2003; 63:4268-74.
16. Jones FS, Jones PL. The tenascin family of ECM glycoproteins: structure, function and regulation during embryonic development and tissue remodeling. Dev Dyn 2000; 218:235-59.
17. Nishimori H, Sasaki Y, Yoshida K, Irifune H, Zembutsu H, Tanaka T, et al. The Id2 gene is a novel target of transcriptional activation by EWS-ETS fusion proteins in Ewing family tumors. Oncogene 2002; 21:8302-9.
18. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366:701-4. (Pubitemid 24036020)
19. Bompard G, Martin M, Roy C, Vignon F, Freiss G. Membrane targeting of protein tyrosine phosphatase PTPL1 through its FERM domain via binding to phosphatidylinositol 4,5-biphosphate. J Cell Sci 2003; 116:2519-30. (Pubitemid 36790133)
20. Kikuchi R, Murakami M, Sobue S, Iwasaki T, Hagiwara K, Takagi A, et al. Ewing's sarcoma fusion protein, EWS/Fli-1 and Fli-1 protein induce PLD2 but not PLD1 gene expression by binding to an ETS domain of 5′ promoter. Oncogene 2007; 26:1802-10.
21. Hahm KB, Cho K, Lee C, Im YH, Chang J, Choi SG, et al. Repression of the gene encoding the TGFbeta type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat Genet 1999; 23:222-7. (Pubitemid 29455398)
22. Campbell PG, Durham SK, Suwanichkul A, Hayes JD, Powell DR. Plasminogen binds the heparin-binding domain of insulin-like growth factor-binding protein-3. Am J Physiol 1998; 275:321-31.
23. Siligan C, Ban J, Bachmaier R, Spahn L, Kreppel M, Schaefer KL, et al. EWS-FLI1 target genes recovered from Ewing's sarcoma chromatin. Oncogene 2005; 24:2512-24.
24. Takahashi A, Higashino F, Aoyagi M, Yoshida K, Itoh M, Kyo S, et al. EWS/ETS fusions activate telomerase in Ewing's tumors. Cancer Res 2003; 63:8338-44.
25. Beauchamp E, Bulut G, Abaan OD, Chen K, Merchant A, Matsui W, et al. GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J Biol Chem 2009; 284:9074-82.
26. Wakahara K, Ohno T, Kimura M, Masuda T, Nozawa S, Dohjima T, et al. EWS-Fli1 upregulates expression of the Aurora A and Aurora B kinases. Mol Cancer Res 2008; 6:1937-45.
27. Thompson L, Chang B, Barsky SH. Monoclonal origins of malignant mixed tumors (carcinosarcomas). Evidence for a divergent histogenesis. Am J Surg Pathol 1996; 20:277-85. (Pubitemid 26071508)
28. May WA, Arvand A, Thompson AD, Braun BS, Wright M, Denny CT. EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. Nat Genet 1997; 17:495-7. (Pubitemid 27518406)
29. Arvand A, Bastians H, Welford SM, Thompson AD, Ruderman JV, Denny CT. EWS/FLI1 upregulates mE2-C, a cyclin-selective ubiquitin conjugating enzyme involved in cyclin B destruction. Oncogene 1998; 17:2039-45.
30. Deneen B, Welford SM, Ho T, Hernandez F, Kurland I, Denny CT. PIM3 proto-oncogene kinase is a common transcriptional target of divergent EWS/ETS oncoproteins. Mol Cell Biol 2003; 23:3897-908.
31. Scotlandi K, Benini S, Nanni P, Lollini PL, Nicoletti G, Landuzzi L, et al. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res 1998; 58:4127-31.
32. Dauphinot L, De Oliveira C, Melot T, Sevenet N, Thomas V, Weissman BE, et al. Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2 and c-Myc expression. Oncogene 2001; 20:3258-65.
33. Wai DH, Schaefer KL, Schramm A, Korsching E, Van Valen F, Ozaki T, et al. Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays. Int J Oncol 2002; 20:441-51.
34. Matsunobu T, Tanaka K, Nakamura T, Nakatani F, Sakimura R, Hanada M, et al. The possible role of EWS-Fli1 in evasion of senescence in Ewing family tumors. Cancer Res 2006; 66:803-11.
35. Tirado OM, Mateo-Lozano S, Villar J, Dettin LE, Llort A, Gallego S, et al. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Cancer Res 2006; 66:9937-47. (Pubitemid 44672046)
36. Cerisano V, Aalto Y, Perdichizzi S, Bernard G, Manara MC, Benini S, et al. Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene 2004; 23:5664-74.
37. Amsellem V, Kryszke MH, Hervy M, Subra F, Athman R, Leh H, et al. The actin cytoskeleton-associated protein zyxin acts as a tumor suppressor in Ewing tumor cells. Exp Cell Res 2005; 304:443-56. (Pubitemid 40321122)
38. Mendiola M, Carrillo J, Garcia E, Lalli E, Hernández T, de Alava E, et al. The orphan nuclear receptor DAX1 is upregulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors. Int J Cancer 2006; 118:1381-9.
39. Smith R, Owen LA, Trem DJ, Wong JS, Whangbo JS, Golub TR, et al. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell 2006; 9:405-16. (Pubitemid 43668735)
40. Carrillo J, Garcia-Aragoncillo E, Azorin D, Agra N, Sastre A, González-Mediero I, et al. Cholecystokinin downregulation by RNA interference impairs Ewing tumor growth. Clin Cancer Res 2007; 13:2429-40. (Pubitemid 46698594)
41. Nagano A, Ohno T, Shimizu K, Hara A, Yamamoto T, Kawai G, et al. EWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A. Int J Cancer 2009.
42. Ban J, Bennani-Baiti IM, Kauer M, Schaefer KL, Poremba C, Jug G, et al. EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma. Cancer Res 2008; 68:7100-9.
43. Potikyan G, Savene RO, Gaulden JM, France KA, Zhou Z, Kleinerman ES, et al. EWS/FLI1 regulates tumor angiogenesis in Ewing's sarcoma via suppression of thrombospondins. Cancer Res 2007; 67:6675-84. (Pubitemid 47105513)
44. Riggi N, Suvà ML, Suvà D, Cironi L, Provero P, Tercier S, et al. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res 2008; 68:2176-85. (Pubitemid 351521790)
45. Herrero-Martín D, Osuna D, Ordóñez JL, Sevillano V, Martins AS, Mackintosh C, et al. Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target. Br J Cancer 2009; 101:80-90.
46. Fuchs B, Inwards C, Scully SP, Janknecht R. hTERT is highly expressed in Ewing's sarcoma and activated by EWS-ETS oncoproteins. Clin Orthop Relat Res 2004; 64-8. (Pubitemid 39167109)
47. Zanini C, Giribaldi G, Mandili G, Carta F, Crescenzio N, Bisaro B, et al. Inhibition of heat shock proteins (HSP) expression by quercetin and differential doxorubicin sensitization in neuroblastoma and Ewing's sarcoma cell lines. J Neurochem 2007; 103:1344-54.
48. Martins AS, Ordóñez JL, García-Sanchez A, Herrero D, Sevillano V, Osuna D, et al. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to antiinsulin- like growth factor 1 receptor treatment: in vitro and in vivo study. Cancer Res 2008; 68:6260-70.
49. Martins AS, Mackintosh C, Martin DH, Campos M, Hernández T, Ordóñez JL, et al. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 2006; 12:3532-40.
50. Gazziola C, Cordani N, Carta S, De Lorenzo E, Colombatti A, Perris R. The relative endogenous expression levels of the IFNAR2 isoforms influence the cytostatic and pro-apoptotic effect of IFNalpha on pleomorphic sarcoma cells. Int J Oncol 2005; 26:129-40.
51. Benini S, Manara MC, Cerisano V, Perdichizzi S, Strammiello R, Serra M, et al. Contribution of MEK/ MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects. Int J Cancer 2004; 108:358-66.
52. Baird K, Davis S, Antonescu CR, Harper UL, Walker RL, Chen Y, et al. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 2005; 65:9226-35. (Pubitemid 41507988)
53. Uren A, Wolf V, Sun YF, Azari A, Rubin JS, Toretsky JA. Wnt/Frizzled signaling in Ewing sarcoma. Pediatr Blood Cancer 2004; 43:243-9.
54. Endo Y, Beauchamp E, Woods D, Taylor WG, Toretsky JA, Uren A, et al. Wnt-3a and Dickkopf-1 stimulate neurite outgrowth in Ewing tumor cells via a Frizzled3-and c-Jun N-terminal kinase-dependent mechanism. Mol Cell Biol 2008; 28:2368-79. (Pubitemid 351429982)
55. Navarro D, Agra N, Pestaña A, Alonso J, González-Sancho JM. The EWS/FLI1 oncogenic protein inhibits expression of the Wnt inhibitor DICKKOPF-1 gene and antagonizes beta-catenin/TCF-mediated transcription. Carcinogenesis 2009.
56. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003; 1653:1-24.
57. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992; 359:162-5.
58. Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, Denny CT. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994; 6:146-51. (Pubitemid 24188594)
59. Maire G, Brown CW, Bayani J, Pereira C, Gravel DH, Bell JC, et al. Complex rearrangement of chromosomes 19, 21 and 22 in Ewing sarcoma involving a novel reciprocal inversion-insertion mechanism of EWS-ERG fusion gene formation: a case analysis and literature review. Cancer Genet Cytogenet 2008; 181:81-92.
60. Ichikawa H, Shimizu K, Hayashi Y, Ohki M. An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res 1994; 54:2865-8. (Pubitemid 24187764)
61. Jeon IS, Davis JN, Braun BS, Sublett JE, Roussel MF, Denny CT, et al. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene 1995; 10:1229-34.
62. Kaneko Y, Yoshida K, Handa M, Toyoda Y, Nishihira H, Tanaka Y, et al. Fusion of an ETS-family gene, EIAF, to EWS by t(17;22)(q12;q12) chromosome translocation in an undifferentiated sarcoma of infancy. Genes Chromosomes Cancer 1996; 15:115-21.
63. Peter M, Couturier J, Pacquement H, Michon J, Thomas G, Magdelenat H, et al. A new member of the ETS family fused to EWS in Ewing tumors. Oncogene 1997; 14:1159-64.
64. Yamaguchi S, Yamazaki Y, Ishikawa Y, Kawaguchi N, Mukai H, Nakamura T. EWSR1 is fused to POU5F1 in a bone tumor with translocation t(6;22)(p21;q12). Genes Chromosomes Cancer 2005; 43:217-22.
65. Mastrangelo T, Modena P, Tornielli S, Bullrich F, Testi MA, Mezzelani A, et al. A novel zinc finger gene is fused to EWS in small round cell tumor. Oncogene 2000; 19:3799-804.
66. Wang L, Bhargava R, Zheng T, Wexler L, Collins MH, Roulston D, et al. Undifferentiated small round cell sarcomas with rare EWS gene fusions: identification of a novel EWS-SP3 fusion and of additional cases with the EWS-ETV1 and EWS-FEV fusions. J Mol Diagn 2007; 9:498-509. (Pubitemid 47434117)
67. Szuhai K, Ijszenga M, de Jong D, Karseladze A, Tanke HJ, Hogendoorn PC. The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology. Clin Cancer Res 2009; 15:2259-68.
68. Mertens F, Wiebe T, Adlercreutz C, Mandahl N, French CA. Successful treatment of a child with t(15;19)-positive tumor. Pediatr Blood Cancer 2007; 49:1015-7. (Pubitemid 350022467)
69. Kawamura-Saito M, Yamazaki Y, Kaneko K, Kawaguchi N, Kanda H, Mukai H, et al. Fusion between CIC and DUX4 upregulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation. Hum Mol Genet 2006; 15:2125-37.
70. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, et al. Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer 2010; 49:40-51.
71. Radig K, Schneider-Stock R, Rose I, Mittler U, Oda Y, Roessner A. p53 and ras mutations in Ewing's sarcoma. Pathol Res Pract 1998; 194:157-62. (Pubitemid 28192782)
72. ARF, p15, TP53 and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet 2000; 120:91-8.
73. Park YK, Chi SG, Kim YW, Park HR, Unni KK. p53 mutations in Ewing's sarcoma. Oncol Rep 2001; 8:533-7.
74. Amir G, Issakov J, Meller I, Sucher E, Peyser A, Cohen IJ, et al. Expression of p53 gene product and cell proliferation marker Ki-67 in Ewing's sarcoma: correlation with clinical outcome. Hum Pathol 2002; 33:170-4.
75. de Alava E, Antonescu CR, Panizo A, Leung D, Meyers PA, Huvos AG, et al. Prognostic impact of p53 status in Ewing sarcoma. Cancer 2000; 89:783-92. (Pubitemid 30658577)
76. Kovar H, Jug G, Aryee DN, Zoubek A, Ambros P, Gruber B, et al. Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 1997; 15:2225-32. (Pubitemid 27493912)
77. Wei G, Antonescu CR, de Alava E, Leung D, Huvos AG, Meyers PA, et al. Prognostic impact of INK4A deletion in Ewing sarcoma. Cancer 2000; 89:793-9. (Pubitemid 30658577)
78. Lopez-Guerrero JA, Pellin A, Noguera R, Carda C, Llombart-Bosch A. Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors. Lab Invest 2001; 81:803-14. (Pubitemid 32553402)
79. Huang HY, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healey JH, et al. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol 2005; 23:548-58. (Pubitemid 46224232)
80. Lessnick SL, Dacwag CS, Golub TR. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell 2002; 1:393-401.
81. Kovar H, Pospisilova S, Jug G, Printz D, Gadner H. Response of Ewing tumor cells to forced and activated p53 expression. Oncogene 2003; 22:3193-204. (Pubitemid 36712931)
82. kip1 in Ewing's family tumors. Clin Cancer Res 2004; 10:1003-12.
83. Maitra A, Roberts H, Weinberg AG, Geradts J. Aberrant expression of tumor suppressor proteins in the Ewing family of tumors. Arch Pathol Lab Med 2001; 125:1207-12.
84. WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem 2003; 278:15105-15.
85. Sakimura R, Tanaka K, Nakatani F, Matsunobu T, Li X, Hanada M, et al. Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors. Int J Cancer 2005; 116:784-92.
86. Brisset S, Schleiermacher G, Peter M, Mairal A, Oberlin O, Delattre O, et al. CGH analysis of secondary genetic changes in Ewing tumors: correlation with metastatic disease in a series of 43 cases. Cancer Genet Cytogenet 2001; 130:57-61.
87. Ozaki T, Paulussen M, Poremba C, Brinkschmidt C, Rerin J, Ahrens S, et al. Genetic imbalances revealed by comparative genomic hybridization in Ewing tumors. Genes Chromosomes Cancer 2001; 32:164-71.
88. Hattinger CM, Potschger U, Tarkkanen M, Squire J, Zielenska M, Kiuru-Kuhlefelt S, et al. Prognostic impact of chromosomal aberrations in Ewing tumours. Br J Cancer 2002; 86:1763-9.
89. Brownhill SC, Taylor C, Burchill SA. Chromosome 9p21 gene copy number and prognostic significance of p16 in ESFT. Br J Cancer 2007; 96:1914-23.
90. Savola S, Nardi F, Scotlandi K, Picci P, Knuutila S. Microdeletions in 9p21.3 induce false negative results in CDKN2A FISH analysis of Ewing sarcoma. Cytogenet Genome Res 2007; 119:21-6.
91. Ferreira BI, Alonso J, Carrillo J, Acquadro F, Largo C, Suela J, et al. Array CGH and gene-expression profiling reveals distinct genomic instability patterns associated with DNA repair and cell cycle checkpoint pathways in Ewing's sarcoma. Oncogene 2008; 27:2084-90.
92. Roberts P, Burchill SA, Brownhill S, Cullinane CJ, Johnston C, Griffiths MJ, et al. Ploidy and karyotype complexity are powerful prognostic indicators in the Ewing's sarcoma family of tumors: a study by the United Kingdom Cancer Cytogenetics and the Children's Cancer and Leukaemia Group. Genes Chromosomes Cancer 2008; 47:207-20.
93. Savola S, Klami A, Tripathi A, Niini T, Serra M, Picci P, et al. Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors. BMC Cancer 2009; 9:17.
94. Tarkkanen M, Kiuru-Kuhlefelt S, Blomqvist C, Armengol G, Bohling T, Ekfors T, et al. Clinical correlations of genetic changes by comparative genomic hybridization in Ewing sarcoma and related tumors. Cancer Genet Cytogenet 1999; 114:35-41.
95. Knuutila S, Armengol G, Bjorkqvist AM, el-Rifai W, Larramendy ML, Monni O, et al. Comparative genomic hybridization study on pooled DNAs from tumors of one clinical-pathological entity. Cancer Genet Cytogenet 1998; 100:25-30.
96. Thompson AD, Teitell MA, Arvand A, Denny CT. Divergent Ewing's sarcoma EWS/ETS fusions confer a common tumourigenic phenotype on NIH3T3 cells. Oncogene 1999; 18:5506-13.
97. Deneen B, Denny CT. Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation. Oncogene 2001; 20:6731-41.
98. Zwerner JP, Guimbellot J, May WA. EWS/FLI function varies in different cellular backgrounds. Exp Cell Res 2003; 290:414-9.
99. Blondheim NR, Levy YS, Ben-Zur T, Burshtein A, Cherlow T, Kan I, et al. Human mesenchymal stem cells express neural genes, suggesting a neural predisposition. Stem Cells Dev 2006; 15:141-64.
100. García-Castro MI, Marcelle C, Bronner-Fraser M. Ectodermal Wnt function as a neural crest inducer. Science 2002; 297:848-51. (Pubitemid 34839637)
101. Hu-Lieskovan S, Zhang J, Wu L, Shimada H, Schofield DE, Triche TJ. EWS-FLI1 fusion protein upregulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's Family of Tumors. Cancer Res 2005; 65:4633-44. (Pubitemid 40740799)
102. Torchia EC, Jaishankar S, Baker SJ. Ewing tumor fusion proteins block the differentiation of pluripotent marrow stromal cells. Cancer Res 2003; 63:3464-8. (Pubitemid 36793021)
103. Castillero-Trejo Y, Eliazer S, Xiang L, Richardson JA, Ilaria RL Jr. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/ FLI-1-dependent, ewing sarcoma-like tumors. Cancer Res 2005; 65:8698-705. (Pubitemid 41377357)
104. Riggi N, Cironi L, Provero P, Suvà M-L, Kaloulis K, Garcia-Echeverria C, et al. Development of Ewing's Sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 2005; 65:11459-68. (Pubitemid 41821703)
105. Burns JS, Abdallah BM, Schrøder HD, Kassem M. The histopathology of a human mesenchymal stem cell experimental tumor model: support for an hMSC origin for Ewing's sarcoma? Histol Histopathol 2008; 23:1229-40.
106. Funes JM, Quintero M, Henderson S, Martinez D, Qureshi U, Westwood C, et al. Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc Natl Acad Sci USA 2007; 104:6223-8.
107. Cironi L, Riggi N, Provero P, Wolf N, Suvà ML, Suvà D, et al. IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells. PLoSOne 2008; 3:2634.
108. Scotlandi K, Avnet S, Benini S, Manara MC, Serra M, Cerisano V, et al. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. Int J Cancer 2002; 101:11-6.
109. Suvà ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC, et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 2009; 69:9211-8.
110. Richter GH, Plehm S, Fasan A, Rössler S, Unland R, Bennani-Baiti IM, et al. EZH2 is a mediator of EWS/ FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci USA 2009; 106:5324-9.
111. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O. Mesenchymal stem cell features of Ewing Tumors. Cancer Cell 2007; 11:421-9.
112. Hancock JD, Lessnick SL. A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle 2008; 7:250-6.
113. Kauer M, Ban J, Kofler R, Walker B, Davis S, Meltzer P, et al. A molecular function map of Ewing's sarcoma. PLoSOne 2009; 4:5415.
114. Riggi N, Stamenkovic I. The Biology of Ewing sarcoma. Cancer Letters 2007; 254:1-10.
115. Suvà ML, Riggi N, Stehle JC, Baumer K, Tercier S, Joseph JM, et al. Identification of cancer stem cells in Ewing's sarcoma. Cancer Res 2009; 69:1776-81.
116. Cironi L, Provero P, Riggi N, Janiszewska M, Suvà D, Suvà ML, et al. Epigenetic features of human mesenchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1. PLoSOne 2009; 4:7904.
117. Ordóñez JL, Martins AS, Osuna D, Madoz-Gúrpide J, de Alava E. Targeting sarcomas: therapeutic targets and their rational. Semin Diagn Pathol 2008; 25:304-16.
118. Gonzalez I, Vicent S, de Alava E, Lecanda F. EWS/ FLI-1 oncoprotein subtypes impose different requirements for transformation and metastatic activity in a murine model. J Mol Med 2007; 85:1015-29.
119. Vormoor J, Baersch G, Decker S, Hotfilder M, Schafer KL, Pelken L, et al. Establishment of an in vivo model for pediatric Ewing tumors by transplantation into NOD/scid mice. Pediatr Res 2001; 49:332-41. (Pubitemid 32205231)
120. Beltinger C, Debatin KM. Murine models for experimental therapy of pediatric solid tumors with poor prognosis. Int J Cancer 2001; 92:313-8. (Pubitemid 32249703)
121. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 2007; 49:928-40.
122. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005; 65:8984-92. (Pubitemid 41377390)
123. Scotlandi K, Benini S, Manara MC, Serra M, Nanni P, Lollini PL, et al. Murine model for skeletal metastases of Ewing's sarcoma. J Orthop Res 2000; 18:959-66.
124. Frese KK, Tuveson DA. Maximizing mouse cancer models. Nat Rev Cancer 2007; 7:645-58.
125. Lin PP, Pandey MK, Jin F, Xiong S, Deavers M, Parant JM, et al. EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. Cancer Res 2008; 68:8968-75.
126. Torchia EC, Boyd K, Rehg JE, Qu C, Baker SJ. EWS/ FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice. Mol Cell Biol 2007; 27:7918-34. (Pubitemid 350086425)
127. Forster A, Pannell R, Drynan LF, Codrington R, Daser A, Metzler M, et al. The invertor knock-in conditional chromosomal translocation mimic. Nat Methods 2005; 2:27-30. (Pubitemid 41131054)
128. Riggi N, Suva ML, Stamenkovic I. Ewing's sarcoma origin: from duel to duality. Expert Rev Anticancer Ther 2009; 9:1025-30.
129. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 2007; 7:233-45. (Pubitemid 46480968)
130. Perez-Losada J, Pintado B, Gutierrez-Adan A, Flores T, Banares-Gonzalez B, del Campo JC, et al. The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice. Oncogene 2000; 19:2413-22. (Pubitemid 30323474)
131. Huettner CS, Zhang P, Van Etten RA, Tenen DG. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 2000; 24:57-60. (Pubitemid 30041421)
132. Higuchi M, O'Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR. Expression of a conditional AML1- ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 2002; 1:63-74.
133. Keller C, Arenkiel BR, Coffin CM, El-Bardeesy N, DePinho RA, Capecchi MR. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 2004; 18:2614-26. (Pubitemid 39453101)
134. Haldar M, Hancock JD, Coffin CM, Lessnick SL, Capecchi MR. A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell 2007; 11:375-88. (Pubitemid 46518310)
135. Metzler M, Forster A, Pannell R, Arends MJ, Daser A, Lobato MN, et al. A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology. Oncogene 2006; 25:3093-103. (Pubitemid 43881551)
136. Perez-Losada J, Sanchez-Martin M, Rodriguez-Garcia MA, Perez-Mancera PA, Pintado B, Flores T, et al. Liposarcoma initiated by FUS/TLS-CHOP: the FUS/ TLS domain plays a critical role in the pathogenesis of liposarcoma. Oncogene 2000; 19:6015-22.
137. de Hooge AS, Berghuis D, Santos SJ, Mooiman E, Romeo S, Kummer JA, et al. Expression of cellular FLICE inhibitory protein, caspase-8, and protease inhibitor-9 in Ewing sarcoma and implications for susceptibility to cytotoxic pathways. Clin Cancer Res 2007; 13:206-14.
138. Fulda S, Küfer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001; 20:5865-77. (Pubitemid 32937956)
139. Kontny HU, Lehrnbecher TM, Chanock SJ, Mackall CL. Simultaneous expression of Fas and nonfunctional Fas ligand in Ewing's sarcoma. Cancer Res 1998; 58:5842-9.
140. Burdach S, van Kaick B, Laws HJ, Ahrens S, Haase R, Körholz D, et al. Allogeneic and autologous stemcell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Düsseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol 2000; 11:1451-62.
141. Al-Faris N, Al Harbi T, Goia C, Pappo A, Doyle J, Gassas A, et al. Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma? Pediatr Blood Cancer 2007; 49:190-5.
142. Burke MJ, Walterhouse DO, Jacobsohn DA, Duerst RE, Kletzel M. Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors. Pediatr Blood Cancer 2007; 49:196-8. (Pubitemid 47041111)
143. Bönig H, Laws HJ, Wundes A, Verheyen J, Hannen M, Kim YM, et al. In vivo cytokine responses to interleukin-2 immunotherapy after autologous stem cell transplantation in children with solid tumors. Bone Marrow Transplant 2000; 26:91-6.
144. Ackermann B, Engel BC, Buttlies B, Zibert A, Burdach S. Transgenic IL-2 expression in Ewing tumor cell lines after transfection with starburst dendrimers and cationic liposomes. Pediatr Hematol Oncol 2002; 19:509-20.
145. Staege MS, Hansen G, Baersch G, Burdach S. Functional and molecular characterization of interleukin-2 transgenic Ewing tumor cells for in vivo immunotherapy. Pediatr Blood Cancer 2004; 43:23-34.
146. + cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells. Int J Hematol 2003; 77:175-9.
147. Verhoeven DH, de Hooge AS, Mooiman EC, Santos SJ, ten Dam MM, Gelderblom H, et al. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol 2008; 45:3917-25.
148. + progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis. Klin Padiatr 2004; 216:176-82.
149. Suminoe A, Matsuzaki A, Hattori H, Koga Y, Hara T. Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors. Pediatr Transplant 2009; 13:746-53.
150. Guo W, Guo Y, Tang S, Qu H, Zhao H. Dendritic cell-Ewing's sarcoma cell hybrids enhance antitumor immunity. Clin Orthop Relat Res 2008; 466:2176-83.
151. Goletz TJ, Mackall CL, Berzofsky JA, Helman LJ. Molecular alterations in pediatric sarcomas: potential targets for immunotherapy. Sarcoma 1998; 2:77-87.
152. Mackall C, Berzofsky J, Helman LJ. Targeting tumor specific translocations in sarcomas in pediatric patients for immunotherapy. Clin Orthop Relat Res 2000; 373:25-31.
153. Meyer-Wentrup F, Richter G, Burdach S. Identification of an immunogenic EWS-FLI1-derived HLA-DR-restricted T helper cell epitope. Pediatr Hematol Oncol 2005; 22:297-308.
154. Jacobs JF, Brasseur F, Hulsbergen-van de Kaa CA, van de Rakt MW, Figdor
155. Yabe H, Tsukahara T, Kawaguchi S, Wada T, Sato N, Morioka H, et al. Overexpression of papillomavirus binding factor in Ewing's sarcoma family of tumors conferring poor prognosis. Oncol Rep 2008; 19:129-34.
156. Berghuis D, de Hooge AS, Santos SJ, Horst D, Wiertz EJ, van Eggermond MC, et al. Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. J Pathol 2009; 218:222-31.
157. Foell JL, Hesse M, Volkmer I, Schmiedel BJ, Neumann I, Staege MS. Membrane-associated phospholipase A1beta (LIPI) is an Ewing tumour-associated cancer/ testis antigen. Pediatr Blood Cancer 2008; 51:228-34.
158. Zhang H, Merchant MS, Chua KS, Khanna C, Helman LJ, Telford B, et al. Tumor expression of 4-1BB ligand sustains tumor lytic T cells. Cancer Biol Ther 2003; 2:579-86.
159. Mackall CL, Rhee EH, Read EJ, Khuu HM, Leitman SF, Bernstein D, et al. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res 2008; 14:4850-8.
160. Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, Houghton PJ. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009; 69:7662-71.
161. Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML, et al. Safety, pharmacokinetics and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2009.
162. Sabbatini P, Korenchuk S, Rowand JL, Groy A, Liu Q, Leperi D, et al. GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther 2009; 8:2811-20.
163. Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM, et al. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res 2009; 69:161-70.
164. García-Aragoncillo E, Carrillo J, Lalli E, Agra N, Gómez-López G, Pestaña A, et al. DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell cycle progression in Ewing's tumor cells. Oncogene 2008; 27:6034-43.
165. Kinsey M, Smith R, Iyer AK, McCabe ER, Lessnick SL. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma. Cancer Res 2009; 69:9047-55.
166. Joo J, Christensen L, Warner K, States L, Kang HG, Vo K, et al. GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors. PLoSOne 2009; 4:7608.
167. Owen LA, Kowalewski AA, Lessnick SL. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. PLoSOne 2008; 3:1965.
168. Tirado OM, MacCarthy CM, Fatima N, Villar J, Mateo-Lozano S, Notario V. Caveolin-1 promotes resistance to chemotherapy-induced apoptosis in Ewing's sarcoma cells by modulating PKCalpha phosphorylation. Int J Cancer 2010; 126:426-36.
169. Hu K, Lee C, Qiu D, Fotovati A, Davies A, Abu-Ali S, et al. Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas. Mol Cancer Ther 2009; 8:3024-35.
170. Guan H, Zhou Z, Gallick GE, Jia SF, Morales J, Sood AK, et al. Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma. Mol Cancer Ther 2008; 7:1807-16.
171. Douglas D, Hsu JH, Hung L, Cooper A, Abdueva D, van Doorninck J, et al. BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression. Cancer Res 2008; 68:6507-15.
172. Sohn EJ, Li H, Reidy K, Beers LF, Christensen BL, Lee SB. EWS/FLI1 Oncogene Activates Caspase 3 Transcription and Triggers Apoptosis In vivo. Cancer Res 2010; 70:1154-63.
173. Reddy K, Zhou Z, Jia SF, Lee TH, Morales-Arias J, Cao Y, et al. Stromal cell-derived factor-1 stimulates vasculogenesis and enhances Ewing's sarcoma tumor growth in the absence of vascular endothelial growth factor. Int J Cancer 2008; 123:831-7.
174. Perbal B, Lazar N, Zambelli D, Lopez-Guerrero JA, Llombart-Bosch A, Scotlandi K, et al. Prognostic relevance of CCN3 in Ewing sarcoma. Hum Pathol 2009; 40:1479-86.
175. Kikuta K, Tochigi N, Shimoda T, Yabe H, Morioka H, Toyama Y, et al. Nucleophosmin as a candidate prognostic biomarker of Ewing's sarcoma revealed by proteomics. Clin Cancer Res 2009; 15:2885-94.
176. Scotlandi K, Remondini D, Castellani G, Manara MC, Nardi F, Cantiani L, et al. Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome. J Clin Oncol 2009; 27:2209-16.
177. Zambelli D, Zuntini M, Nardi F, Manara MC, Serra M, Landuzzi L, et al. Biological indicators of prognosis in Ewing's sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP). Int J Cancer 2010; 126:41-52.
178. Cheung IY, Feng Y, Danis K, Shukla N, Meyers P, Ladanyi M, et al. Novel markers of subclinical disease for Ewing family tumors from gene expression profiling. Clin Cancer Res 2007; 13:6978-83.
179. Avigad S, Naumov I, Ohali A, Jeison M, Berco GH, Mardoukh J, et al. Short telomeres: a novel potential predictor of relapse in Ewing sarcoma. Clin Cancer Res 2007; 13:5777-83.
180. Schaefer KL, Eisenacher M, Braun Y, Brachwitz K, Wai DH, Dirksen U, et al. Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer 2008; 44:699-709.
181. Bachmaier R, Aryee DN, Jug G, Kauer M, Kreppel M, Lee KA, et al. O-GlcNAcylation is involved in the transcriptional activity of EWS-FLI1 in Ewing's sarcoma. Oncogene 2009; 28:1280-4.
182. Klevernic IV, Morton S, Davis RJ, Cohen P. Phosphorylation of Ewing's sarcoma protein (EWS) and EWS-Fli1 in response to DNA damage. Biochem J 2009; 418:625-34.
183. Avigad S, Shukla S, Naumov I, Cohen IJ, Ash S, Meller I, et al. Aberrant methylation and reduced expression of RASSF1A in Ewing sarcoma. Pediatr Blood Cancer 2009; 53:1023-8.
184. Gangwal K, Sankar S, Hollenhorst PC, Kinsey M, Haroldsen SC, Shah AA, et al. Microsatellites as EWS/ FLI response elements in Ewing's sarcoma. Proc Natl Acad Sci USA 2008; 105:10149-54.
185. Gangwal K, Lessnick SL. Microsatellites are EWS/ FLI response elements: genomic "junk" is EWS/FLI's treasure. Cell Cycle 2008; 7:3127-32.
186. Guillon N, Tirode F, Boeva V, Zynovyev A, Barillot E, Delattre O. The oncogenic EWS-FLI1 protein binds in vivo GGAA microsatellite sequences with potential transcriptional activation function. PLoSOne 2009; 4:4932.
187. Luo W, Gangwal K, Sankar S, Boucher KM, Thomas D, Lessnick SL. GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance. Oncogene 2009; 28:4126-32.
188. Magwere T, Myatt SS, Burchill SA. Manipulation of oxidative stress to induce cell death in Ewing's sarcoma family of tumours. Eur J Cancer 2008; 44:2276-87
189. Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Yuan L, et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med 2009; 15:750-6.
190. Carrillo J, Agra N, Fernández N, Pestaña A, Alonso J. Devazepide, a nonpeptide antagonist of CCK receptors, induces apoptosis and inhibits Ewing tumor growth. Anticancer Drugs 2009; 20:527-33.
191. Lu G, Punj V, Chaudhary PM. Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL. Cancer Biol Ther 2008; 7:603-8. (Pubitemid 351847039)
192. Nakamura T, Tanaka K, Matsunobu T, Okada T, Nakatani F, Sakimura R, et al. The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells. Int J Oncol 2007; 31:803-11.
193. Bettayeb K, Tirado OM, Marionneau-Lambot S, Ferandin Y, Lozach O, Morris JC, et al. Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases. Cancer Res 2007; 67:8325-34.
194. Timeus F, Crescenzio N, Fandi A, Doria A, Foglia L, Cordero di Montezemolo L. In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines. Oncol Rep 2008; 19:353-9.
195. Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L, et al. NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 2010; 16:530-40.
196. Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, et al. Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 2010.
197. Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, et al. Initial testing of topotecan by the pediatric preclinical testing program. Pediatr Blood Cancer 2009. (Pubitemid 351555544)
198. Zhou Z, Bolontrade MF, Reddy K, Duan X, Guan H, Yu L, et al. Suppression of Ewing's sarcoma tumor growth, tumor vessel formation and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy. Clin Cancer Res 2007; 13:4867-73. (Pubitemid 47294794)
199. Guan H, Zhou Z, Cao Y, Duan X, Kleinerman ES. VEGF165 promotes the osteolytic bone destruction of ewing's sarcoma tumors by upregulating RANKL. Oncol Res 2009; 18:117-25.
200. Wang YX, Mandal D, Wang S, Hughes D, Pollock RE, Lev D, et al. Inhibiting Platelet-derived Growth Factor beta Reduces Ewing's Sarcoma Growth and Metastasis in a Novel Orthotopic Human Xenograft Model. In Vivo 2009; 23:903-9.
201. Schadler KL, Zweidler-McKay PA, Guan H, Kleinerman ES. Delta-Like Ligand 4 Plays a Critical Role in Pericyte/Vascular Smooth Muscle Cell Formation during Vasculogenesis and Tumor Vessel Expansion in Ewing's Sarcoma. Clin Cancer Res 2010; 16:848-56.
202. Yu L, Su B, Hollomon M, Deng Y, Facchinetti V, Kleinerman ES. Vasculogenesis Driven by Bone Marrow-Derived Cells Is Essential for Growth of Ewing's Sarcomas. Cancer Res 2010.
203. Dalal S, Burchill SA. Preclinical evaluation of vascular- disrupting agents in Ewing's sarcoma family of tumours. Eur J Cancer 2009; 45:713-22.
204. Dubois SG, Marina N, Glade-Bender J. Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data. Cancer 2010; 116:749-57.